CD47 and neoplasm: The combination of anti-CD47 therapy with glutamine blockade during radiotherapy—a strategy in which CD47, an immune checkpoint receptor, shields cells from macrophage phagocytosis—results in significant tumor growth suppression, induction of ferroptosis, and prolonged survival in mouse models (112, 113).